In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with elevation of liver transaminases
Timeframe: up to 21 days
Number of participants with neutropenia
Timeframe: up to 21 days
Number of participants with decreased platelet count
Timeframe: up to 21 days
Frequency of observed and reported adverse events
Timeframe: baseline up to 90 days following the last administration of study treatment or study discontinuation/termination, whichever is earlier
Frequency of death
Timeframe: baseline up to 90 days following the last administration of study treatment or study discontinuation/termination, whichever is earlier